Enfamil Premature LIPIL
This article was originally published in The Tan Sheet
Executive Summary
New preterm infant formula contains same levels of docosahexaenoic acid, arachidonic acid as regular LIPIL, Mead Johnson says. Launching this month in 3 oz., ready-to-use bottles, formula will be distributed to hospitals, healthcare professionals and direct to consumers through a toll-free number. Mead announced July 9 FDA had no concerns regarding its premarket notification for the product. BMS division says formula's growth, development benefits for preterm infants are demonstrated by studies presented at Pediatric Academic Societies' annual meeting in May (1"The Tan Sheet" April 29, 2002, p. 22). Similac Advance marketer Ross Products says it also expects to launch fortified preterm formula upon agency clearance of its premarket notification. Abbott Labs' division's second quarter sales were flat at $515 mil., company announced July 11...
You may also be interested in...
DHA, ARA Benefit Preterm Infants, Research Shows; Formulas On Horizon
Infant formula fortified with docosahexaenoic acid (DHA) and arachidonic acid (ARA) provide significant growth benefits over non-fortified formula in preterm infants, study results indicate
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.